Group 1 - The "China Optics Valley 3551 International Entrepreneurship Competition and Talent Fund 10th Anniversary Conference" was held in Wuhan, showcasing the achievements of the Optics Valley Talent Fund, which has invested in over 440 companies with a total fund size of 4.992 billion yuan, leveraging nearly 10 times social capital [1][2] - The "3551 Talent Plan" has attracted nearly 400 projects to settle in Optics Valley over the past 16 years, with the competition expanding its reach to global innovation hubs like Silicon Valley, London, and Tokyo, resulting in over 5,000 project entries [2][3] - The newly established Optics Valley Venture Capital Group aims to promote early-stage, small, long-term, and hard technology investments, creating a matrix-style "Optics Valley Capital" system to empower technological and industrial innovation [4] Group 2 - The conference saw the awarding of 11 sub-funds as "Optics Valley 3551 Talent Fund Partners," emphasizing investment in early-stage and hard technology ventures [3] - The Optics Valley region currently hosts 71 listed companies and over 5,800 high-tech enterprises, with a total of more than 167,000 companies, indicating a robust entrepreneurial ecosystem [4] - The establishment of 51 venture capital funds with a total scale of 12.1 billion yuan, including three seed funds of 250 million yuan each, reflects a strong commitment to supporting innovation and entrepreneurship [4]

责任编辑： 张家祺 近年来，我省完善优质中小企业梯度培育政策体系，加强差异化精准指导和常态化监测帮扶，分层级、 分产业建立专精特新企业培育库。 政策落地过程中，我省围绕财政、融资、创新、服务等关键环节协同发力。在财政支持方面，争取中央 财政资金5.6亿元、安排省级资金3.6亿元，支持专精特新"小巨人"企业打造新动能、攻坚新技术、开发 新产品、强化产业链配套能力。在融资促进方面，在全国率先推出"专精特新贷"业务，遴选57家金融机 构，累计发放信用类贷款395.15亿元，示范带动各类贷款投放2244.76亿元，为专精特新企业提供精准化 融资服务。在提升创新能力方面，组织大中小企业融通对接活动，开展大企业"发榜"中小企业"揭榜"工 作，引导企业攻克产业技术难题，提升中小企业的配套支撑能力。在公共服务供给方面，构建省、市、 县三级中小企业公共服务体系，融入全国中小企业服务"一张网"建设，围绕产业和企业发展需求，建设 服务平台矩阵，引导服务活动、服务资源向专精特新企业倾斜，持续擦亮"专精特新"金字招牌。（记者 陈辉） 1月12日，记者从省工业和信息化厅获悉，2025年全省新增专精特新"小巨人"企业54家、省级专精特新 ...

当前，世界百年未有之大变局加速演进，全球经济格局、产业布局、投资规则正在经历深刻调整，以人 工智能、绿色科技为代表的新质生产力加速崛起，既为双向投资合作带来了在新兴领域布局的全新机 遇，也对传统合作模式的转型升级提出了严峻挑战。最新发布的《中国双向投资报告2025》显示，2024 年中国双向投资结构持续优化、质量稳步提升。我国继续成为全球最具吸引力的投资目的地之一，作为 全球第三大外资流入国，对外直接投资流量和存量也连续多年稳居全球前三，这为江苏进一步深化双向 投资合作奠定了坚实基础、创造了有利环境。 江苏作为全国重要的经济大省、开放大省，始终处在对外开放的前沿，实际使用外资规模约占全国总量 的六分之一，连续多年保持全国第一，对外投资规模与质量也始终处于全国前列，形成了"引进 来"与"走出去"相互促进的良好态势。雄厚的产业基础、完善的供应链网络、活跃的创新资源和优越的 营商环境，构成了江苏拓展双向投资合作空间的综合优势。站在新的历史起点，江苏正肩负起在推进中 国式现代化中"走在前、做示范"的重大责任，要以双向投资合作的"广度"与"深度"为核心，着力打造具 有世界聚合力的双向开放枢纽。而紧紧依托国内大循环所驱动 ...

Core Insights - Wuxi has demonstrated significant growth in its capital market, with a total of 56 new listed companies during the 14th Five-Year Plan period, ranking 7th nationally among cities [1][2] - The city has a strong focus on high-tech industries, with nearly 90% of new listings since 2020 being high-tech enterprises, particularly in integrated circuits, biomedicine, and high-end equipment manufacturing [2][5] - Wuxi's financial ecosystem is robust, with over 600 billion yuan in registered funds and a leading position in QFLP fund numbers and scale in Jiangsu province [3][4] Capital Market Performance - During the 14th Five-Year Plan, Wuxi's listed companies raised a total of 144.6 billion yuan, with a return rate of 49.8% and cumulative cash dividends of 72.27 billion yuan [1][2] - In 2025, Wuxi added 8 new listed companies, raising 7.374 billion yuan, with A-share companies showing revenue and profit growth above the overall A-share market [1][2] Financial Ecosystem - Wuxi has established a strong financial infrastructure, with over 370 equity investment firms registered in the past four years, and a total fund scale exceeding 600 billion yuan [3][4] - The city has created a conducive environment for private equity funds, with significant investments in emerging sectors like artificial intelligence and biomanufacturing [6][7] Government Support and Policy - The local government has been proactive in fostering a supportive environment for capital market development, including initiatives like the "Listing通" service platform and various funding policies for technology innovation [6][8] - Wuxi's government has organized numerous events to promote project financing and has facilitated communication with major stock exchanges to enhance local companies' access to capital [6][9] Industry Development - Wuxi is focusing on building a competitive industrial innovation ecosystem, with plans to support the national goal of self-sufficient industrial supply chains [4][5] - The city is home to nearly 400 companies poised for listing, indicating a strong pipeline for future capital market activity [4][5]

Core Viewpoint - The company has invested 30 million yuan in the Jinan Mingxin Industrial Investment Fund, acquiring a 22.54% share of the total subscribed capital, aligning with its strategic focus on the "big health" sector [1][2]. Group 1: Investment Details - The company acts as a limited partner in the fund, contributing 30 million yuan, which represents 22.54% of the total subscribed capital of 133.1 million yuan [2][16]. - The fund has an operational period of 8 years, with a 4-year investment phase [2][21]. - The investment does not require approval from the company's board or shareholders and is not classified as a related party transaction or a major asset restructuring [3][1]. Group 2: Fund Management and Structure - The fund is managed by Shanghai Mingxin Private Equity Fund Management Partnership, which is responsible for investment decisions and daily operations [9]. - The management fee is set at 1.5% per year during the investment period and 2% per year during the recovery period [10]. - Profit distribution follows a specific order, prioritizing the return of capital to limited partners before any profit sharing [11][18]. Group 3: Investment Focus and Strategy - The fund aims to invest in equity of growth-stage companies in the biopharmaceutical and healthcare sectors, seeking capital appreciation [12]. - The exit mechanisms include project exit distributions, partner withdrawals, and share transfers, ensuring flexibility for limited partners [13][14]. Group 4: Impact on the Company - This investment aligns with the company's strategic development and industry chain layout, leveraging professional investment experience and resources for long-term growth [23]. - The investment will not significantly impact the company's daily operations and will not be included in the company's consolidated financial statements [23].

Group 1 - The core viewpoint of the articles highlights the explosive growth of China's merger and acquisition (M&A) fund market in 2025, driven by the release of policy dividends from the China Securities Regulatory Commission, with a focus on hard technology sectors such as semiconductors and biomedicine [1] - As of December 1, 2025, 29 new M&A funds were established in China, targeting a fundraising scale of approximately 105 billion yuan, representing a 70% year-on-year increase in the number of new funds and over 200% increase in target fundraising scale compared to 2024 [1] - The participation of state-owned platforms and guiding funds in the M&A fund market has increased by 6 percentage points year-on-year, while corporate investors have risen by nearly 10 percentage points, indicating a shift towards industry-driven capital [1] Group 2 - Despite the growth in M&A funds, the number of industry funds established by listed companies remains at a historically low level, reflecting a cautious market attitude following the high valuations and blind cross-border M&A trends of 2014-2015 [2] - Local governments have shown a strong enthusiasm for establishing M&A funds, with around ten provinces and cities, including Shanghai and Shenzhen, implementing supportive policies since September 2024 [2] - The revised "Major Asset Restructuring Management Measures for Listed Companies" in May 2025 has clarified arrangements such as "reverse linkage" for private placement lock-up periods, further stimulating the establishment of M&A funds [3]

转自：成都日报锦观 我市新增20家院士（专家）创新工作站 覆盖人工智能、新材料、生物医药、低空经济等领域 1月12日，记者从市科协获悉，2025年成都市院士（专家）创新工作站新增20家，全市累计建站达300 家，五年来柔性引进两院院士（团队）等高层次专家171名。 记者梳理发现，新建的20家工作站签约了包括中国工程院院士邓龙江在内的31名院士（专家），开展合 作项目33项。值得注意的是，此次新增工作站签约的院士（专家）不少来自省外高校和科研机构。其 中，中国科学院院士刘昌明、郭柏灵分别来自中国科学院地理科学与资源研究所、北京应用物理与计算 数学研究所，还有来自华中科技大学、重庆大学等高校院所的院士（专家）。 据了解，2025年度经批准新建的成都市院士（专家）创新工作站，给予每家25万元的一次性资助。"我 们将持续优化院士（专家）创新工作站服务体系，引导产业园区、科技企业深化与院士（专家）团队的 创新合作，聚焦产业关键技术攻关和产品研发，不断提升企业自主创新能力，加速推进'科产融 合'。"市科协相关负责人告诉记者。 全市累计建站300家 近年来，成都不断优化院士（专家）创新工作站服务体系，依托工作站为产业园区、 ...

Core Viewpoint - Recently, Kelong Botai Biopharmaceutical (Shanghai) Co., Ltd. was established with a registered capital of 5 million RMB, fully owned by Sichuan Kelong Botai Biopharmaceutical Co., Ltd. [1] Company Summary - The legal representative of Kelong Botai Biopharmaceutical (Shanghai) Co., Ltd. is Ding Nanchao [1] - The company operates in the field of scientific research and technical services, specifically in research and experimental development [1] - The registered address is located at 500 Lane 500, Furonghua Road, Pudong New District, Shanghai [1] - The company type is a limited liability company, wholly owned by a natural person [1] - The business scope includes medical research and experimental development (excluding human stem cells, gene diagnosis, and treatment technology development and application), import and export of goods, and technology import and export [1] Business Activities - The company is involved in various activities such as technical services, technical development, technical consulting, technical communication, technical transfer, and technical promotion [1] - It also organizes cultural and artistic exchange activities, conference and exhibition services (with overseas exhibitions subject to approval), marketing planning, corporate management consulting, and information technology consulting services [1]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Chengdu Zenitar Biomedical Technology Co., Ltd. 成都賾靈生物醫藥科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 警告 本公告乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會 （「證監會」）的要求而刊發，僅用作提供資料予香港公眾人士。 閣下閱覽本公告，即代表 閣下知悉、接納並向本公司、本公司的聯席保薦人、 整體協調人、顧問或承銷團成員表示同意： 1 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 本公告並不構成向任何司法權區的公眾人士提呈出售任何證券的招股章程、發售通函、通知、 通函、宣傳冊或廣告，亦不構成出售要約或向公眾人士勸誘或招攬收購、購買或認 ...

1月12日，天眼查融资历程显示，成都赜灵生物医药科技股份有限公司近日获得"C轮"融资，涉及融资 金额近6亿人民币，投资机构为5Y News｜赜灵生物完成近6亿元C轮融资。 资料显示，成都赜灵生物医药科技股份有限公司法定代表人为陈俐娟，成立于2019年，位于成都市，是 一家以从事科技推广和应用服务业为主的企业。企业注册资本48916.2275万人民币，并已于2026年完成 了C轮，交易金额近6亿人民币。 通过天眼查大数据分析，成都赜灵生物医药科技股份有限公司共对外投资了1家企业，知识产权方面有 商标信息7条，专利信息38条，此外企业还拥有行政许可7个。 天眼查信息显示，成都赜灵生物医药科技股份有限公司的股东为：陈俐娟、贵州百灵企业集团制药股份 有限公司、成都众信汇智企业管理合伙企业（有限合伙）、QM288 Limited、嘉兴裕禧股权投资合伙企 业（有限合伙）。 来源：市场资讯 ...